The World’s First and Only Sinusoidal-Formed Trifocal Intraocular Lens

Presented at the ESCRS Satellite Symposium

VSY Biotechnology Offers “A New Approach to Trifocal Intraocular Lens Technology”

The  European Cataract and Refractive Surgery Association held their 36th annual meeting from September 22nd to 26th, 2018. This meeting included an examination of trifocal intraocular lenses (IOLs)  produced with advanced technology. Specifically, VSY Biotechnology shared the features and clinical results of AcrivaUD Trinova IOLs that they developed after extensive R&D studies. These lenses were also discussed in the Satellite Symposium, under the subject heading, “A New Approach to Trifocal Intraocular Lens Technology.” Physicians that had implanted AcrivaUD Trinova to their patients throughout the world shared with the ophthalmology sector their knowledge about the special features and innovations of these lenses.

Dr. Roberto Belluci from Italy and Dr. Marko Hawlina from Slovenia participated in the Satellite Symposium as moderators. The symposium speakers were Dr. Ruth Lapid-Gortzak from the Netherlands, Dr. Minoru Tomita from Japan, Dr. Ewa Mrukwa-Kominek from Poland, and Dr. Johan Blanckaert from Belgium. The physicians talked about their experiences implanting the intraocular lenses in their patients and the results they obtained.

During the annual meeting, which was visited by more than 10,000 visitors from all around the world, VSY Biotechnology met with ophthalmologists and introduced to them to its innovative products. As part of this series of introductions, specialists from different countries presented their experiences with AcrivaUD Trinova at the VSY Biotechnology booth and answered questions from the ophthalmologists in attendance. Moreover, one of the speakers in the symposium, Dr. Johan Blanckaert, also submitted, and presented, an abstract about AcrivaUD Trinova.

AcrivaUD Trinova lenses, produced with Sinusoidal Vision Technology (SVT ), enable cataract patients to see the near, intermediate, and far distances without any glasses. Ophthalmologists remove the eye’s natural lens and then apply the AcrivaUD Trinova lenses. These lenses represent a significant innovation in the world of eye care, allowing cataract patients to see better and more consistently. Due to the groundbreaking nature of these lenses, VSY Biotechnology has already completed worldwide patent applications for AcrivaUD Trinova lenses.

VSY Biotechnology CEO Özge Altunbaş Göktekin expressed her pride and happiness in participating in ESCRS, one of the most important organizations in the world in the ophthalmology field. Göktekin stated that VSY was excited to introduce their newest product incorporating superior technology, and would continue “to talk about the new technology that we contributed to the area of ophthalmology.” Göktekin added that, “in the Satellite Symposium, we found the chance to talk about all aspects of Trinova with specialists developing lenses in different countries. We also addressed the innov

START TYPING AND PRESS ENTER TO SEARCH